LIFE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LIFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. aTyr Pharma's accounts receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. aTyr Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $1.08.
The historical data trend for aTyr Pharma's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
aTyr Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), aTyr Pharma's accounts receivable are only considered to be worth 75% of book value:
aTyr Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (98.166 | + | 0.75 * 0 | + | 0.5 * 0 | - | 30.183 |
- | 0 | - | -0.188) | / | 63.2864 | ||
= | 1.08 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of aTyr Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Sanjay Shukla | officer: Chief Medical Officer | C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121 |
Paul Schimmel | director | 88 SIDNEY ST, CAMBRIDGE MA 02139 |
Jill Marie Broadfoot | officer: Chief Financial Officer | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Sara Zaknoen | director | C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121 |
John K Clarke | director | C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542 |
Nancy Krueger | officer: See Remarks | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Svetlana Lucas | director | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Jane A Gross | director | 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
John Mendlein | director, officer: CEO and Executive Chairman | |
Ecor1 Capital Fund Qualified, L.p. | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ashraf Amanullah | officer: Vice President, Manufacturing | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
John T Blake | officer: Vice President, Finance | C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342 |
Timothy P Coughlin | director | 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075 |
Jeffrey S. Hatfield | director | 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
David John King | officer: See Remarks | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
From GuruFocus
By Stock market mentor Stock market mentor • 02-06-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 08-09-2023
By Value_Insider Value_Insider • 11-18-2022
By Stock market mentor Stock market mentor • 01-19-2023
By sperokesalga sperokesalga • 06-06-2023
By sperokesalga sperokesalga • 06-09-2023
By Marketwired • 06-22-2023
By sperokesalga sperokesalga • 03-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.